Tab-Cel Gets EU Fast-Track Nod; Nefecon Reverts To Standard Review
Atara Plans November Filing As Calliditas Expects Three-Month Approval Decision Delay
The outcomes of a handful of requests for accelerated assessment at the European Medicines Agency appear not yet to be in the public domain. In the meantime, there's been good for news for Atara's tab-cel and a switch to standard review for Nefecon from Calliditas.
